These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 22192350)

  • 1. Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome.
    Panidis D; Tziomalos K; Macut D; Delkos D; Betsas G; Misichronis G; Katsikis I
    Fertil Steril; 2012 Feb; 97(2):494-500. PubMed ID: 22192350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.
    Panidis D; Tziomalos K; Misichronis G; Papadakis E; Betsas G; Katsikis I; Macut D
    Hum Reprod; 2012 Feb; 27(2):541-9. PubMed ID: 22144419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life.
    Pinola P; Puukka K; Piltonen TT; Puurunen J; Vanky E; Sundström-Poromaa I; Stener-Victorin E; Lindén Hirschberg A; Ravn P; Skovsager Andersen M; Glintborg D; Mellembakken JR; Ruokonen A; Tapanainen JS; Morin-Papunen LC
    Fertil Steril; 2017 Mar; 107(3):788-795.e2. PubMed ID: 28089571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
    Graff SK; Mário FM; Alves BC; Spritzer PM
    Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin resistance in polycystic ovary syndrome: hyperandrogenemia versus normoandrogenemia.
    Yildiz BO; Gedik O
    Eur J Obstet Gynecol Reprod Biol; 2001 Dec; 100(1):62-6. PubMed ID: 11728659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.
    Diamanti-Kandarakis E; Kouli CR; Bergiele AT; Filandra FA; Tsianateli TC; Spina GG; Zapanti ED; Bartzis MI
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4006-11. PubMed ID: 10566641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome.
    Sung YA; Oh JY; Chung H; Lee H
    Fertil Steril; 2014 Mar; 101(3):840-5. PubMed ID: 24424368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
    Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Macut D; Panidis D
    Hum Reprod; 2013 Mar; 28(3):785-93. PubMed ID: 23315058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents.
    Li L; Chen X; He Z; Zhao X; Huang L; Yang D
    J Pediatr Adolesc Gynecol; 2012 Dec; 25(6):390-5. PubMed ID: 23089573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
    Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
    Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
    Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
    Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vigorous exercise is associated with superior metabolic profiles in polycystic ovary syndrome independent of total exercise expenditure.
    Greenwood EA; Noel MW; Kao CN; Shinkai K; Pasch LA; Cedars MI; Huddleston HG
    Fertil Steril; 2016 Feb; 105(2):486-93. PubMed ID: 26551442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smoking is associated with increased free testosterone and fasting insulin levels in women with polycystic ovary syndrome, resulting in aggravated insulin resistance.
    Cupisti S; Häberle L; Dittrich R; Oppelt PG; Reissmann C; Kronawitter D; Beckmann MW; Mueller A
    Fertil Steril; 2010 Jul; 94(2):673-7. PubMed ID: 19394003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome.
    Moghetti P; Tosi F; Bonin C; Di Sarra D; Fiers T; Kaufman JM; Giagulli VA; Signori C; Zambotti F; Dall'Alda M; Spiazzi G; Zanolin ME; Bonora E
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E628-37. PubMed ID: 23476073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
    Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
    J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome.
    Zhang L; Fang X; Li L; Liu R; Zhang C; Liu H; Tan M; Yang G
    J Endocrinol Invest; 2018 Dec; 41(12):1401-1407. PubMed ID: 29785700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?
    Ozkaya E; Cakir E; Cinar M; Kara F; Baser E; Cakir C; Kucukozkan T
    Gynecol Endocrinol; 2012 Jun; 28(6):468-71. PubMed ID: 22103710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raising threshold for diagnosis of polycystic ovary syndrome excludes population of patients with metabolic risk.
    Quinn MM; Kao CN; Ahmad A; Lenhart N; Shinkai K; Cedars MI; Huddleston HG
    Fertil Steril; 2016 Oct; 106(5):1244-1251. PubMed ID: 27445197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
    Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
    Reprod Health; 2015 Jan; 12():7. PubMed ID: 25595199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.